The upper limit price of Tremfya, Janssen's autoimmune disease treatment, is expected to be reduced under the price-volume agreement system for the second consecutive year. 

According to industry sources, the National Health Insurance Service and Janssen recently finalized PVA negotiations for the reimbursement of Tremfya on the 1st.

In December last year, Tremfya’s upper price limit was also lowered from KRW 1.59 million to KRW 1.55 million under the price-volume agreement Type I negotiations.

If the price of the drug is reduced again this year, it will be the second consecutive year that the upper limit has been adjusted under the PVA system.